3 news items
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
WVE
15 May 24
market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
WVE
9 May 24
and capabilities in human genetics, computational biology, omics technologies and gene editing, responsible for harnessing the latest methods and technologies
Wave Life Sciences Announces Approval Of First Clinical Trial Application For RestorAATion-2 Trial Of WVE-006 In Individuals With Alpha-1 Antitrypsin Deficiency
WVE
30 Apr 24
in serum, in 2024.GSK has the exclusive global license for WVE-006. Development and commercialization responsibilities will transfer to GSK
- Prev
- 1
- Next